Research Use Only Application: Antibody conjugation Reagent for Targeted cell death, Targeted cell death for cancer cells, High-throughput screening with cell killing assays oYo-Link VcMMAF is an Antibody-Drug Conjugation Reagent allowing for site-specific labeling of Monomethyl Auristatin F. labels to the heavy-chains of oYo-Link-compatible antibodies with up to two labels per antibody. VcMMAF is an anti-mitotic agent linked via the lysosomally cleavable dipeptide, valine-citrulline (vc). oYo-Link limits the attachment of the VcMMAF drugs to the heavy chains of the antibody and therefore ensures that the drug label does not interfere with antibody binding. Furthermore, site-specific labeling limits 1-2 VcMMAF drugs to be attached per antibody, providing precise antibody-drug conjugate ratios. The antibody labeling procedure simply requires mixing oYo-Link VcMMAF with the desired antibody followed by photocrosslinking with non-damaging black light (365 nm). Photocrosslinking can be carried in most buffers, including those containing amine-containing molecules (e.g. TRIS, glycine) or storage proteins (see Buffer Compatibility Table). Catalog AT7003 Requirements: To label your compatible antibodies with oYo-Link, you will need a Light Source emitting at 365nm (6-10W). Use your own Compatible Device from our list or purchase AlphaTheras LED Photo-Crosslinking Device. Technical Support: For science questions or questions concerning compatibility email support alphathera.com
Concentration:
270 µg/mL
Molecular Weight:
8 kDa
Buffer:
PBS
Form:
Dried pellet
oYo-Link VcMMAF Product Icon
* VAT and and shipping costs not included. Errors and price changes excepted
